The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

References

• Burger JA . Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep.7(1), 26–33 (2012).
   PubMed Web of Science ®Google Scholar
• Hallek M . Signaling the end of chronic lymphocytic leukemia: new frontline. treatment strategies. Blood122(23), 3723–3734 (2013).
   PubMed Web of Science ®Google Scholar
• Campo E , SwerdlowSH, HarrisNL, PileriS, SteinH, JaffeES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood117(19), 5019–5032 (2011).
   PubMed Web of Science ®Google Scholar
• Gribben JG , O’BrienS. Update on therapy of chronic lymphocytic leukemia. J. Clin. Oncol.29(5), 544–550 (2011).
   PubMed Web of Science ®Google Scholar
• Hallek M , ChesonBD, CatovskyDet al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood111(12), 5446–5456 (2008).
   PubMed Web of Science ®Google Scholar
• Rai KR , PetersonBL, AppelbaumFRet al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343(24), 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Hallek M , FischerK, Fingerle-RowsonGet al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet376(9747), 1164–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Badoux XC , KeatingMJ, WangXet al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood117(11), 3016–3024 (2011).
   PubMed Web of Science ®Google Scholar
• Fischer K , CramerP, BuschRet al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol.29(26), 3559–3566 (2011).
   PubMed Web of Science ®Google Scholar
• Zaja F , MianM, VolpettiSet al. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am. J. Hematol.88(11), 955–960 (2013).
   PubMed Web of Science ®Google Scholar
• Eichhorst B , DreylingM, RobakT, MontserratE, HallekM. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.22(Suppl. 6), vi50–vi54 (2011).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas Version I. 2013. National Comprehensive Cancer Network Website. www.nccn.org
   Google Scholar
• Honigberg LA , SmithAM, SirisawadMet al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in modes of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA.107(29), 13075–13080 (2010).
   PubMed Web of Science ®Google Scholar
• Khan WN . Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol. Res.23(2–3), 147–156 (2001).
   PubMed Web of Science ®Google Scholar
• Wiestner A . Targeting B-cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J. Clin. Oncol.31(1), 128–130 (2013).
   PubMed Web of Science ®Google Scholar
• de Rooij MFM , KuilA, GeestCet al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood119(11), 2590–2594 (2012).
   PubMed Web of Science ®Google Scholar
• Pan Z , ScheerensH, LiSJet al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. Chem. Med. Chem.2(1), 58–61 (2007).
   Google Scholar
• Advani RH , BuggyJJ, SharmanJPet al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol.31(1), 88–94 (2012).
   PubMed Web of Science ®Google Scholar
• Byrd JC , FurmanRR, CoutreSEet al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med.369(1), 32–42 (2013).
   PubMed Web of Science ®Google Scholar
• O’Brien S , FurmanRR, CoutreSEet al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, Phase 1b/2 trial. Lancet Oncol.15(1), 48–58 (2013).
   PubMed Web of Science ®Google Scholar
• Hallek M , ChesonBD, CatovskyDet al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood (2012). http://bloodjournal.hematologylibrary.org
   Google Scholar
• Woyach JA , SmuckerK, SmithLLet al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood123(12), 1810–1817 (2014).
   PubMed Web of Science ®Google Scholar
• Jaglowski SM , JonesJA, FlynnJMet al. A Phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J. Clin. Oncol.30(Suppl.) Abstract 6508, (2012).
   Google Scholar
• Brown JR , BarrientosJC, BarrPMet al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a Phase 1b study. Blood122(21), Abstract 525 (2013).
   Web of Science ®Google Scholar
• Burger JA , KeatingMJ, WierdaWGet al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a Phase II trial in 40 patients. Blood122(21), Abstract 675 (2013).
   Web of Science ®Google Scholar
• Hillmen P . Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am. Soc. Hematol. Educ. Program2011, 104–109 (2011).
   PubMedGoogle Scholar
• Maddocks KJ , LinTS. Update in the management of chronic lymphocytic leukemia. J. Hematol. Oncol.2(29), 1–8 (2009).
   PubMedGoogle Scholar
• O’Brien PC , FlemingTR. A multiple testing procedure for clinical trials. Biometrics35(3), 549–556 (1979).
   PubMed Web of Science ®Google Scholar